Physician profile
Matthew E Cepeda
NPI 1841356862
$1,899.26
in general payments reported to CMS, 2019-2025
21 companies · $265 in 2025
The $265 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $25.90 · 2021: $165 · 2022: $276 · 2023: $315 · 2024: $287 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $491.02 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $354.29 | 2019-2022 | |
| Genzyme Corporation | $188.03 | 2022-2023 | |
| Sanofi Pasteur INC. | $155.93 | 2020-2025 | |
| Comsort, INC | $150.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $92.29 | 2024-2025 | |
| Pfizer INC. | $90.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $74.92 | 2019-2022 | |
| Glaxosmithkline, LLC. | $41.91 | 2019-2023 | Bexsero |
| Supernus Pharmaceuticals, INC. | $29.93 | 2021-2024 | Qelbree |
| Tris Pharma INC | $29.53 | 2022 | |
| Seqirus USA INC | $29.08 | 2025 | Flucelvax |
| Neos Therapeutics, Lp | $28.80 | 2023-2024 | Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $28.10 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $25.65 | 2024 | Flumist Quadrivalent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $18.88 | 2023 | |
| Ironwood Pharmaceuticals, INC | $18.12 | 2024 | |
| Cipher Pharmaceuticals US LLC | $15.59 | 2025 | Natroba, Spinosad |
| Medline Industries Lp | $13.02 | 2019 | |
| Adlon Therapeutics L.P. | $12.24 | 2021 | |
| Kaleo, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cepeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.